Table 6.
EHR cohort (n = 367): Concomitant medication at index
| Treatment | n (%) |
|---|---|
| ASTHMA MEDICATIONS | 367 (100.0%) |
| Inhaled corticosteroids (ICS) | 215 (58.6) |
| Long-acting ß2-agonists (LABA) | 124 (33.8) |
| ICS/LABA combination | 208 (56.7) |
| Adrenergic in combination with anticholinergics | 5 (1.4) |
| Short acting | 5 (1.4) |
| Long acting | NA |
| Leukotriene modifiers (LTRA) | 113 (30.8) |
| Methylxanthines | 4 (1.1) |
| Anti-IgE treatment | NA |
| Short-acting ß2-agonists (SABA) | 256 (69.8) |
| Systemic corticosteroids (OCS) | 367 (100.0) |
| Anticholinergics | 21 (5.7) |
| - Short acting | 9 (2.5) |
| - Long acting | 13 (3.5) |
| Omalizumab | NA |
| PD4 antagonists | NA |
| N-acetylcysteine | 126 (34.3) |
| Cardiovascular medications (ANY) | 155 (42.2) |
| Anti-dyslipidaemias | 50 (13.6) |
| Statins | 48 (13.1) |
| Fibrates | 1 (0.3) |
| Anti-hypertensives | 90 (24.5) |
| Beta-blockers | 47 (12.8) |
| ACEs | 29 (7.9) |
| ARBs | 44 (12.0) |
| Other medications | 111 (30.2) |
| Antibiotics | 169 (46.0) |
| Anti-virus | 11(3.0) |
| Anti-allergy | 3 (0.8) |
| Cough and cold | 223 (60.8) |
| Antihistamines | 201 (54.8) |
| Nasal corticosteroids | 162 (44.1) |
| Antidepressant | 65 (17.7) |
| Hypnotics | 46 (12.5) |
| Antianxiety | 63 (17.2) |
| Bifosfonates | 10 (2.7) |
| Calcium D vitamine | 2 (0.5) |
NA = value not found or zero